Determinants Of Antibody Response After Recombinant Gp160 Boosting In Vaccinia-Naive Volunteers Primed With Gp160-Recombinant Vaccinia Virus

Barney S. Graham, Geoffrey J. Gorse, David H. Schwartz, Michael C. Keefer, M. Juliana McElrath, Thomas J. Matthews, Peter F. Wright, Robert B. Belshe, Mary Lou Clements, Raphael Dolin, Lawrence Corey, Dani P. Bolognesi, Donald M. Stablein, Joy R. Esterlitz, Shiu-Lok Hu, Gale E. Smith, and the National Institute of Allergy and Infectious Diseases AIDS Vaccine Clinical Trials Network Vanderbilt University School of Medicine, Nashville, Tennessee; Duke University Medical Center, Durham, North Carolina; St. Louis University School of Medicine, St. Louis, Missouri; University of Rochester School of Medicine and Dentistry, Rochester, New York; Bristol-Myers/Squibb Pharmaceutical Research Institute and University of Washington School of Medicine, Seattle, Washington; MicroGeneSys, Inc., Meriden, Connecticut; Johns Hopkins School of Hygiene and Public Health and School of Medicine, Baltimore, EMMES Corporation, Potomac, and Vaccine Research and Development Branch, Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland